"In mixed-HIV status couples, the combination of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) and antiretroviral (ARV) treatment nearly eliminates transmissions, MedPage Today reports. Researchers reported preliminary results from the ongoing Partners Demonstration Project at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

These results suggest that this paradigm of PrEP use—when the HIV-negative member of a couple actually adheres to PrEP until his or her partner has an undetectable viral load—would offer a risk reduction that’s likely even greater than 96 percent.